Company Legal Name
Latest Valuation
Founded Year
Headquarter
PathAI, Inc. develops cloud-based artificial intelligence solutions that enable pathologists to analyze tissue samples with enhanced accuracy and efficiency. Founded in 2016 and headquartered in Boston, the company leverages machine learning algorithms to assist in diagnostic pathology, helping healthcare providers improve patient outcomes through more precise disease detection and treatment recommendations. PathAI's platform addresses critical challenges in pathology, including diagnostic variability and workflow inefficiencies that plague traditional manual analysis methods. The company focuses on expanding its AI-powered diagnostic capabilities across various disease areas while building strategic partnerships with pharmaceutical companies, research institutions, and healthcare systems to accelerate adoption of precision medicine solutions.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





